Abstract Library

#3009 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Gastroenteropancreatic NeuroEndocrine TumoRs Starting LAnreotide Autogel–Baseline Characteristics

Introduction: Information provided to patients (pts) with neuroendocrine tumors (NETs) about burden and treatment proposed may influence pts’ adherence to treatment, outpatient monitoring and quality of life (QoL), but can also cause anxiety.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hautefeuille V

Authors: Hautefeuille V, Do Cao C, Coriat R, Dominguez S, Mineur L,

Keywords: Patients’ perception of information, Quality of Life, Lanreotide,

#1901 Portal Hypertension-Related Digestive Hemorrhage in Patients with Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (pNET) can cause portal hypertension (PHT)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: MULLER N

Authors: Muller N, Zappa M, Hammel P, De Mestier L, Laurent L,

Keywords: portal hypertension,

#1284 Pharmacokinetic (PK) Differences Between Subcutaneous and Intramuscular Administration of Lanreotide: Results from a Phase I Study

Introduction: Data have shown that 38% of intended gluteal intramuscular (IM) injections with long-acting release octreotide were mistakenly given subcutaneously (SC); in carcinoid syndrome patients, this significantly increased the rate of flushing (P=0.005; Boyd 2013, Pancreas). Lanreotide depot(LD) recently became FDA-approved for the treatment of gastroenteropancreatic neuroendocrine tumors (120 mg Q4W) as a deep SC injection.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Manon A

Authors: Manon A, Wolin E, Chassaing C, Lewis A, Bertocchi L,

Keywords: lanreotide, Somatuline, pharmacokinetic, PK,

#1137 Contrast Harmonic Endoscopic Ultrasonography (CH-EUS) is Able to Predict Aggressivity in Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (PNET) are a heterogeneous group regarding malignancy.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Palazzo M, Palazzo L, Aubert A, Maire F, Fabre M,

Keywords: pancreatic neuroendocrine tumor, CH-EUS,

#1124 Correlation Between the 18F-FDG Uptake and Pathological Data in Well-Differentiated Digestive and Pulmonary Neuroendocrine Tumors (NET)

Introduction: The 18F-FDG uptake assessed by PET/CT is correlated to prognosis in most tumors.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Bucau M, Laurent-Bellue A, Cros J, Hentic O, Rebours V,

Keywords: Neuroendocrine tumors, PET-scan, 18-FDG, Ki67, VHL, metabolism,